Loading…
Hindustan Unilever Ltd
NSE: HINDUNILVR BSE: 500696 INE030A01027 Fast Moving Consumer Goods FMCG 🔎 Screen
NIFTY 50 NIFTY 100 NIFTY 200 NIFTY 500 FMCG MNC +1 more
₹45 Cr
Market Cap
44.7
P/E
3.17
PEG
28.4%
ROCE
31.0%
ROE
0.03
D/E
23.3%
OPM
-22.4%
% from 52W High
24
α RS
⚖️ Compare 🔒 Generate Report 📚 Guides
📈 Price History
Ratio Health
Excellent
Good
Average
Poor
By Category
Shareholding
About

Hindustan Unilever is in the FMCG business comprising primarily of Home Care, Beauty & Personal Care and Foods & Refreshment segments. The Company has manufacturing facilities across the country and sells primarily in India.

✓ Strengths 2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 92.4%
! Concerns 3
  • Stock is trading at 10.1 times its book value
  • The company has delivered a poor sales growth of 6.51% over past five years.
  • Earnings include an other income of Rs.4,933 Cr.
Key Ratios Snapshot
📊 Sector Averages
📈 Growth Pattern
📊 Quick Scorecard
Loading…
🔒
Premium Feature
AI-generated 10-section company profile — business model, financials, strengths, risks & management quality
Upgrade to Premium
Already a member? Log in
📐
3-Statement Financial Model
Bear / Base / Bull projections · DCF fair value · Reverse-DCF
Open Model →
Mixed but improving: 10% USG was the highest in 13 quarters with 5% volume growth, but EBITDA margin fell 40bps YoY and reported PAT declined 2% on a one-off tax base. quarter Investor Presentation One-Pager? Jun 2026
Revenue
₹17,184 Cr
+10% YoY (USG); underlying volume growth 5%
EBITDA Margin
23.0%
-40bps YoY; EBITDA ₹3,947 Cr, +8% YoY
PAT
₹2,680 Cr
Reported PAT -2% YoY due to JQ'25 one-off tax credit; PAT before exceptional items ₹2,731 Cr, +9% YoY
Key Metric
USG 10%
Highest growth in 13 quarters; driven equally by volume and price
What Went Right
  • Consolidated USG of 10% was the highest in 13 quarters, with underlying volume growth of 5% and turnover of ₹17,184 Cr.
  • Home Care delivered 14% USG, its best growth in three years, led by high-single digit UVG; Fabric Wash and Household Care grew double-digits.
  • Beauty & Wellbeing posted 12% USG with double-digit growth in Premium Skin Care and Hair Care; Minimalist delivered double-digit growth with sequential acceleration.
  • EBITDA grew 8% YoY to ₹3,947 Cr and PAT before exceptional items grew 9% to ₹2,731 Cr, despite commodity volatility.
  • Coffee delivered double-digit, volume-led growth and Lifestyle Nutrition continued double-digit momentum; Boost crossed the ₹1,000 Cr annual turnover milestone.
What to Watch
  • Reported PAT declined 2% YoY to ₹2,680 Cr because JQ'25 had a one-off tax credit, so headline profit still went backwards.
  • EBITDA margin contracted 40bps YoY to 23.0%, with palm oil inflation persisting for the second consecutive year and commodity/currency volatility continuing.
  • Personal Care was the weakest segment at 4% USG with low-single digit volume decline; growth was price-led rather than volume-led.
  • Health & Wellbeing underperformed, with OZiva soft as the business transitions; no numeric recovery timeline was provided.
  • The margin guidance is only qualitative and remains at 'around the current guided range', with no explicit FY27 number despite inflationary pressure.
Investor Lens
The thesis is modestly strengthened: 5% underlying volume growth shows the portfolio and channel investments are working in Home Care and Beauty & Wellbeing, while Personal Care's 4% USG and volume decline shows inflation and competitive pressure are still unresolved. EBITDA margin erosion of 40bps and a reported PAT decline on an adverse tax base mean the quality of the beat is less clean than the headline USG suggests. Management expects FY'27 to be better than FY'26 but has not given a numeric target, and margin guidance remains qualitative around the current range. Watch monsoon progress, palm oil prices, OZiva's stabilisation, and whether Personal Care volumes turn positive; the 4 September 2026 Capital Markets Day could provide more concrete medium-term targets.
From investor presentation · AI-generated analysis · Not investment advice
🔒
Premium Feature
Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance
Upgrade to Premium
Already a member? Log in
📊 MIXED Revenue grows 10% YoY but PAT dips 3.2%.
Revenue
Revenue rose 10.1% YoY to ₹17,341 Cr, with sequential growth of 6.1% indicating strong demand. Volume-led growth likely drove top-line expansion.
Profitability
Net profit fell 3.2% YoY to ₹2,680 Cr and dropped 10.5% QoQ, despite revenue growth. EPS declined from ₹11.73 to ₹11.38, impacted by higher costs or tax rate.
Margins
Operating margin held steady at 23% YoY and QoQ, with operating profit up 8.5% YoY. Cost controls balanced input pressures to maintain OPM.
Cash Flow
Insufficient data provided to comment on cash flow quality relative to PAT.
Balance Sheet
Debt-to-equity is a low 0.03, reflecting minimal leverage. ROCE of 28.4% and ROE of 31% indicate strong capital efficiency.
Key Risks
Declining profit despite revenue growth signals margin compression risk. High PE of 44.7x leaves little room for earnings misses. Competitive intensity and input cost volatility could pressure future margins.
Outlook
Revenue momentum is positive, but profit weakness raises caution. Sustained volume growth and cost management will be key to restoring profitability in coming quarters.
Generated by AI · Jun 2026 results · Not investment advice
🔒
Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free AccountLog In
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to PremiumCreate Free Account
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Documents.

Access concall transcripts, annual reports, credit ratings, and investor presentations.

Upgrade to PremiumCreate Free Account

Revenue by Segment

Segment Q3FY26 Q4FY26 Trend
Beauty & Wellbeing
3,930
EBIT 1,025
3,697
EBIT 1,076
Discontinued operations
178
EBIT -73
0
EBIT 0
Foods
3,689
EBIT 773
3,566
EBIT 721
Home Care
5,887
EBIT 1,100
6,344
EBIT 1,209
Others (includes Exports)
565
EBIT 132
515
EBIT 70
Personal Care
2,370
EBIT 421
2,229
EBIT 417
Total 16,619 16,351

Source: NSE Integrated Filing XBRL (Reg. 33 Ind AS). Values in ₹ Crore.

📊 Sector KPIs

Industry-specific KPIs with historical trend — AI-extracted from investor presentations
🔒
Premium Feature
Industry-specific KPIs with historical trend across quarters — AI-extracted from investor presentations
Upgrade to Premium
Already a member? Log in
🔒
Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to PremiumCreate Free Account

📊 Analysis Methodology

This comprehensive investment analysis was conducted using The Finmagine™ Stock Analysis & Ranking Methodology, a proprietary framework that systematically evaluates stocks across five critical dimensions: Financial Health, Growth Prospects, Competitive Positioning, Management Quality, and Valuation.

🎯
Discover Our Proven Investment Framework Learn how we analyze and rank stocks using advanced quantitative models, multi-dimensional scoring systems, and dynamic discriminatory ranking techniques that have guided successful investment decisions across market cycles.
📊 Explore The Finmagine™ Methodology

A comprehensive, bias-free framework for analyzing and ranking stocks by Financial Strength, Growth Potential, Competitive Edge, Management Quality, and Value.

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including equities and mutual funds, involves inherent risks, including the potential loss of principal. All investments are subject to market fluctuations, regulatory changes, and other risks that may affect their value. Past performance is not indicative of future results. This report is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This report does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a SEBI-registered investment adviser or other qualified financial professional before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities or financial instruments discussed in this report. Any such positions, if material, are disclosed to the best of the author's knowledge and are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company, institution, or third party.

Information Sources:
The analysis and opinions expressed herein are based on publicly available information, including but not limited to company filings with the BSE/NSE, annual reports, management commentary, investor presentations, data from the Reserve Bank of India (RBI), SEBI, industry publications, and other reliable financial data sources. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This report may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. The author does not undertake any obligation to update such statements in the future.

Regulatory Compliance:
This report is intended to comply with the Securities and Exchange Board of India (Research Analysts) Regulations, 2014, as amended, and other applicable Indian laws and regulations.

Limitation of Liability:
The content of this report is provided "as is" without any warranties, express or implied, including accuracy, completeness, merchantability, or fitness for a particular purpose. The author and publisher expressly disclaim any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.